<div><em>Wockhardt posted an almost five-fold jump in its net profit in the June quarter on the back of strong growth in sales in Britain and India,</em></div><div><em><strong>CH Unnikrishnan</strong> reports</em></div><div> </div><div>Habil Khorakiwala-led drugmaker Wockhardt Ltd, which is struggling with its US sales due to manufacturing compliance issues with US drug regulator, posted an almost five-fold jump in its net profit in the June quarter on the back of strong growth in sales in Britain and India.</div><div> </div><div>The company posted a net profit of Rs 114.2 crore during the quarter as against the year-ago quarter's Rs 19.95 crore. Its sales increased to Rs 1,179.4 crore in the quarter ended June 30, 2015 from Rs 1,005.18 crore a year ago.</div><div> </div><div>Wockhardt's UK business backed by effective business development efforts achieved consistent strong quarterly performance and grew by 55 per cent (in £terms 59 per cent) during the quarter. India business of the company continued to grow significantly at 27 per cent with new product launches and focused sales strategies, the company said on Monday.</div><div> </div><div>However, the company's US sales remained in the red after the Food and Drug Administration (FDA) banned the imports from its export facilities in India since September 2014. US sales, which contributed 20 per cent of the company's overall sales declined 21 per cent this quarter as compared to June quarter in 2014.</div><div> </div><div>Wokhardt shares closed at Rs 1,652.25 a unit, up 3.47 per cent on the BSE on Monday, while the benchmark index Sensex was up 0.4 per cent to close at 28,101.72 points.</div>
